MedSurg and Neurotechnology — Segment operating income
Stryker MedSurg and Neurotechnology — Segment operating income increased by 3.1% to $1.10B in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 19.3%, from $924.00M to $1.10B. Over 3 years (FY 2021 to FY 2024), MedSurg and Neurotechnology — Segment operating income shows an upward trend with a 12.6% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase signals improved profitability and operational efficiency, while a decrease suggests rising costs or declining pricing power.
Detailed definition
Calculated as the segment's net sales minus its cost of sales, R&D, and SG&A expenses. This metric serves as the primary...
Peer comparison
The standard measure of segment-level profitability used by analysts to compare business units across peers.
syk_segment_medsurg_and_neurotechnology_segment_operating_incomeHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $702.00M | $663.00M | $807.00M | $611.00M | $601.00M | $626.00M | $899.00M | $627.00M | $780.00M | $859.00M | $1.07B | $804.00M | $861.00M | $924.00M | $1.42B | $970.00M | $1.07B | $1.10B |
| QoQ Change | — | -5.6% | +21.7% | -24.3% | -1.6% | +4.2% | +43.6% | -30.3% | +24.4% | +10.1% | +24.6% | -24.9% | +7.1% | +7.3% | +53.1% | -31.4% | +10.2% | +3.1% |
| YoY Change | — | — | — | — | -14.4% | -5.6% | +11.4% | +2.6% | +29.8% | +37.2% | +19.0% | +28.2% | +10.4% | +7.6% | +32.2% | +20.6% | +24.2% | +19.3% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Stryker's medsurg and neurotechnology — segment operating income?
- Stryker (SYK) reported medsurg and neurotechnology — segment operating income of $1.10B in Q3 2025.
- How has Stryker's medsurg and neurotechnology — segment operating income changed year-over-year?
- Stryker's medsurg and neurotechnology — segment operating income increased by 19.3% year-over-year, from $924.00M to $1.10B.
- What is the long-term trend for Stryker's medsurg and neurotechnology — segment operating income?
- Over 3 years (2021 to 2024), Stryker's medsurg and neurotechnology — segment operating income has grown at a 12.6% compound annual growth rate (CAGR), from $2.81B to $4.00B.
- What does medsurg and neurotechnology — segment operating income mean?
- The profit earned by the MedSurg and Neurotechnology segment from its core operations.